| abstract |
The present invention provides for a domain antibody (dAb) that binds to CD28 and prevents the binding of CD28 to CD80 and/or CD86, but does not cross-react with CTLA4. Pharmaceutical compositions comprising thereof and uses of the antibody thereof in the preparation of medicaments for the treatment of diseases, including autoimmune diseases or graft-related diseases, are also provided. |